RFA for Superficial Lipomas

Last updated: March 24, 2025
Sponsor: Columbia University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Warts

Treatment

STARMed VIVA Combo RF System

Clinical Study ID

NCT06903208
AAAV2254
  • Ages > 18
  • All Genders

Study Summary

Lipomas are non-cancerous growths of fatty tissue that develop under the skin in approximately 1 in 1000 people, though this number may be higher. While rarely symptomatic, they often cause emotional distress due to the unappealing appearance of the mass. Treatment of unsightly lipomas is excision with local anesthetic in the office or with sedation in the operating room. The recovery period is short and the procedure is low risk; however, the result of the operation is a visible scar over the site of the lipoma. Many patients defer surgical excision because excision of a lipoma is a cosmetic procedure, but the aesthetic outcome is undesirable.

Radiofrequency ablation (RFA) is a technique that applies heat generated by a high frequency, alternating current to soft tissue. The hyperthermia produced by the current causes tissue necrosis that ablates the tissue into which the energy is directed. RFA has been successfully applied to thyroid nodules, pancreatic lesions, esophageal dysplasia and liver tumors. However, the manufacturers of the RFA technology have been focused on its application in pre-malignant and malignant lesions and have not yet considered its application to benign tumors. This study will test the success of RFA for superficial lipomas as a non-surgical option for treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients >18 years old

  • Patients with a lipoma <5 cm, above the fascia on the trunk, abdomen or extremities

Exclusion

Exclusion Criteria:

  • Lipomas of the face or neck

  • Angiolipomas (identified on exam as a firm, mobile, occasionally discolored mass)

  • Patients with history of hereditary retinoblastoma, Li-Fraumeni syndrome, familialadenomatous polyposis, neurofibromatosis, tuberous sclerosis and Werner syndrome

  • A history of exposure to herbicides, arsenic and dioxin

  • A history of radiation treatment for other cancers

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: STARMed VIVA Combo RF System
Phase:
Study Start date:
June 01, 2025
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Columbia University Irving Medical Center

    New York, New York 10032
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.